Can-ming Chen

发表

Fiberoptic ductoscopy combined with cytology testing in the patients of spontaneous nipple discharge

Guangyu Liu, Jiong Wu, Zhen-zhou Shen, 2008, Breast Cancer Research and Treatment.

Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer

Keda Yu, Z. Shao, Can-ming Chen, 2012, PloS one.

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Xin Hu, L. Fan, Junjie Li, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and Safety of Docetaxel Combined With Oxaliplatin as a Neoadjuvant Chemotherapy Regimen for Chinese Triple-Negative Local Advanced Breast Cancer Patients: A Prospective, Open, and Unicentric Phase II Clinical Trial

Z. Shao, Guangyu Liu, Jiong Wu, 2013, American journal of clinical oncology.

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

Jiong Wu, Z. Shao, Can-ming Chen, 2013, World Journal of Surgical Oncology.

Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.

Guangyu Liu, Jiong Wu, G. Di, 2008, Anticancer research.

Identification of a Comprehensive Spectrum of Genetic Factors for Hereditary Breast Cancer in a Chinese Population by Next-Generation Sequencing

Xin Hu, Menghong Sun, Guangyu Liu, 2015, PloS one.

Tumor Associated Macrophage × Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer

W. Jin, Jiong Wu, Z. Shao, 2012, PloS one.

Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer

Z. Shao, Can-ming Chen, R. Zhou, 2012, Annals of Surgical Oncology.

Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.

Keda Yu, Z. Shao, Guangyu Liu, 2012, The oncologist.

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial

Hong-wei Zhang, L. Fan, Keda Yu, 2019, Cancer.

Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy

Z. Shao, Can-ming Chen, Sheng Chen, 2015, Oncotarget.

Lymph Node Counts and Ratio in Axillary Dissections Following Neoadjuvant Chemotherapy for Breast Cancer: A Better Alternative to Traditional pN Staging

Jiong Wu, Z. Shao, Can-ming Chen, 2013, Annals of Surgical Oncology.

A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline‐containing neoadjuvant chemotherapy for breast cancer

Keda Yu, Z. Shao, Can-ming Chen, 2012, Journal of surgical oncology.

Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months

Guangyu Liu, Jiong Wu, Z. Shao, 2009, BMC Cancer.

The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.

Guangyu Liu, Jiong Wu, G. Di, 2021, Gland surgery.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Jiong Wu, Z. Shao, Jiong Wu, 2010, Oncology reports.

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Keda Yu, Z. Shao, Jiong Wu, 2013, The oncologist.

ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy

Keda Yu, Z. Shao, Guangyu Liu, 2014, PloS one.

Bmc Cancer

Guangyu Liu, Jiong Wu, Z. Shao, 2022 .

The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation

Yajia Gu, Jiong Wu, Junjie Li, 2014, PloS one.

Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis

Z. Shao, Can-ming Chen, Sheng Chen, 2016, Breast Cancer Research and Treatment.

Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing

Guangyu Liu, Jiong Wu, G. Di, 2016, PloS one.

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

Xin Hu, L. Fan, Keda Yu, 2021 .

Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy.

Fang Liu, Xia Meng, Jiong Wu, 2011, Cancer letters.

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy

Junjie Li, Guangyu Liu, Jiong Wu, 2016, Oncotarget.

[A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer].

Guangyu Liu, Jiong Wu, Z. Shao, 2006, Zhonghua wai ke za zhi [Chinese journal of surgery].

PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy

Y. Chen, Z. Shao, F. Wu, 2012, Cancer Chemotherapy and Pharmacology.